- Innate Pharma (IPHA, Financial) proposes to shift its governance structure to align with international standards at the AGM on May 22, 2025.
- The new board will consist of eight members, including two new appointments, Christian Itin and Marty J. Duvall.
- The governance change aims to simplify operations and respond to investor feedback.
Innate Pharma S.A. (Nasdaq: IPHA) has announced plans to overhaul its corporate governance structure, proposing a transition from an executive board/supervisory board model to a CEO/board of directors model. This move is set to be decided at the company’s Annual General Meeting (AGM) scheduled for May 22, 2025. This strategic change aims to streamline governance and align the company with international standards, reflecting a proactive response to feedback from investors.
Under the proposed changes, Irina Staatz-Granzer, currently the Chairwoman of the Supervisory board, would be appointed as the Chairwoman of the board of Directors. Jonathan Dickinson, the current Chairman of the Executive board, would be elevated to the role of CEO. The reshaped board will incorporate eight members, with the addition of Christian Itin, CEO of Autolus, and Marty J. Duvall, a seasoned biotech executive.
Current board members Hervé Brailly, Gilles Brisson, and Jean-Yves Blay will not transition to the new board of Directors. This transformation is part of Innate Pharma's strategy to enhance its governance framework, responding to investor concerns and positioning the company to meet global governance standards effectively.
